HIV-2 diagnoses remain low in the United States, differentiation test use studied
HIV-2 diagnoses remain low in the United States, report finds
A U.S. report on trends in HIV-2 diagnoses and HIV-1/HIV-2 differentiation test use found diagnoses of HIV-2 remain low. The report suggests…
HIV-2 diagnoses stay low in the U.S., but current testing methods could be updated to work better.
Phase 3 trial compares switch to doravirine/islatravir versus continuing bictegravir/FTC/TAF in HIV-1
Phase 3 trial compares two HIV drug regimens for people already virologically suppressed.
A phase 3 randomized controlled trial enrolled 643 virologically suppressed adults with HIV-1 to compare switching to doravirine/islatravir …
People with HIV already on effective treatment can safely switch to a new two-drug pill without losing virus control, according to a complet…
Bictegravir-lenacapavir single-tablet regimen non-inferior to complex regimens for HIV-1 suppression at 48 weeks
Can a single daily pill control HIV as well as complex multi-pill regimens?
In this phase 3 randomized trial of 557 virologically suppressed adults with HIV-1 on complex regimens, switching to once-daily oral bictegr…
A new single daily pill kept HIV suppressed just as well as complex multi-pill regimens in a trial of 557 adults who had been on treatment f…